Using all RCTs, case series, and case reports included in the pooled analysis, we will determine the incidences of all-grade and high-grade irAEs, which may highlight the high risk of irAEs associated with anti-PD-1 and anti-PD-L1 drugs in the treatment of NSCLC. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.